Sharekhan's research report on Mastek
Mastek expects a 40-50% growth in UK healthcare revenue next year, driven by the new government’s modernisation plan and increased AI and data investments, despite short-term decision-making delays stemming from the NHS England merger with the DHSC. Company is streamlining its North American operations, increasing Data & AI investments, and targeting both tier-2 ($1-10 billion revenue) and Fortune 500 customers along with focus on Healthcare and Manufacturing verticals. Margins are expected to face short-term pressure from new UK healthcare contracts and North America reorganization costs, but AI efficiencies and refined go-to-market strategy aims to restore profitability in 12-36 months.
Outlook
We reiterate Buy with unchanged PT of Rs 3,030. At CMP, the stock trades at 19.9/18/15.3x its FY25/26/27E EPS.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
